Warning Letter Roundup & Recap – Oct. 24, 2017
Executive Summary
US FDA outlined quality systems and Medical Device Reporting troubles in three device-related warning letters this week, including one addressed to Magellan Diagnostics for ongoing regulatory issues. A fourth letter dinged a firm for failing to have pre-market clearance for its products.
You may also be interested in...
Magellen Gets Warning Letter On Lead Test Concerns
The warning letter alleges the company sold modified versions of its blood lead tests without alerting US FDA, and didn’t tell the agency about reported discrepancies in test results. FDA first warned of possible faulty test results in May.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.